TIMOTHY O'NEIL: Open Payments
NPI 1447779400 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$645 in 29 payments from 13 companies in 2025. Trend: 2023 $199 · 2024 $275 · 2025 $645
Food & beverage: $645
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 7 | $160 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $156 |
| Abbott Laboratories | 3 | $60 |
| ABBVIE INC. | 3 | $52 |
| Amgen Inc. | 2 | $48 |
| Madrigal Pharmaceuticals | 1 | $28 |
| GlaxoSmithKline, LLC. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Novo Nordisk Inc | 1 | $20 |
Products named: JARDIANCE, FREESTYLE LIBRE 3, EVENITY, UBRELVY, REZDIFFRA, BEXSERO, Veozah, MOUNJARO.
Industry payments across CA — which companies pay providers there.
